Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells
Graft-versus-host disease (GVHD) is a frequent and severe complication of hematopoietic stem cell transplantation (HSC), and is responsible for significant early mortality despite prophylactic strategies developed in recent decades, Especially since it is resistant to first-line treatment.
The present diagnosis is difficult, non-specific and is based on the combination of an evocative clinical context (CSH allograft, time to appearance before J100, characteristic clinical manifestations), suggestive anatomo-pathological analysis (predominantly inflammatory infiltrate Lymphocyte, mucosal edema and presence of apoptotic bodies), and the exclusion of any differential diagnosis (in particular serology / negative viral PCR).
However, to date there is no molecular characterization of this manifestation, and therefore no specific treatment.
The nCounter® nanostring technology allows the rapid and simple analysis of the simultaneous expression of a group of genes (up to 800 on the same sample), from a very small amount of RNA, and from samples with difficulty Such as fabrics already fixed to formaldehyde and included in paraffin. It allows the detection of a "molecular signature" of the tissue analyzed.
No transcriptomic analysis has ever been performed on human tissues with GVHD.
調査の概要
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
Picardie
-
Amiens、Picardie、フランス、80054
- 募集
- CHU Amiens Picardie
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Person aged ≥ 18 years
- Patients who have received an HSC allograft since June 2012
- Having presented a suspicion of cutaneous or digestive GVHD before J100 post-allograft
- Of which the diagnosis was retained by the combination of clinical and histological criteria
- Or whose diagnosis has been reversed by histological analysis, for the reactive / inflammatory biopsies that serve as control
- The diagnosis of which was made between 01/01/2013 and 31/12/2015
- Survived at least 1 month to monitor clinical progress
Exclusion Criteria:
- Whose biopsy specimens were also the sites of a viral reactivation (EBV, CMV, HHV) that could mimic a GVHD
- Having survived less than 1 month after the diagnosis of GVHD
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Transcriptomic profile by analysis of the expression of the mRNAs of a determined panel of 800 genes regulating the immune response
時間枠：3 months
|
3 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。